Medtronic Secures FDA 510(k) for MiniMed Go MDI System Targeting 15M MDI Patients
Medtronic won FDA 510(k) clearance for its MiniMed Go Smart MDI system integrating InPen and Abbott’s Instinct sensor, with U.S. launch slated this spring to serve over 15 million patients on multiple daily injections. Executives told investors they have ‘significant firepower’ to pursue further acquisitions.
1. Medtronic Bolsters Acquisition Capacity
At the JP Morgan Healthcare Conference in San Francisco, Medtronic executives confirmed the company has over $15 billion in available liquidity and generates roughly $5 billion in free cash flow annually, providing “significant firepower” to pursue strategic acquisitions. With net debt to adjusted EBITDA at approximately 2.4x—well within its 3x covenant threshold—Medtronic is positioned to add complementary technologies in areas such as cardiovascular, diabetes care and neuroscience. Management highlighted a disciplined approach, targeting deals that can deliver at least 15 percent internal rate of return and accelerate its long-term revenue growth beyond the low-to-mid single digits it has delivered organically over the past three years.
2. Precision Neuroscience Partnership Advances Neurosurgical Platform
Medtronic announced a strategic collaboration with Precision Neuroscience to integrate the Layer 7™ cortical interface—featuring 128-channel high-resolution electrodes—with its StealthStation™ surgical navigation system. The co-developed solution is designed to provide neurosurgeons with simultaneous real-time structural imaging and functional brain mapping in the operating room. In early feasibility studies, the combined platform reduced intraoperative decision latency by 30 percent and enabled surgeons to localize epileptogenic tissue with sub-millimeter accuracy. Precision plans a pivotal trial in 2027 with enrollment of 200 patients undergoing tumor resections and functional mapping procedures.
3. FDA Clears MiniMed Go™ Smart MDI System
Medtronic Diabetes secured FDA 510(k) clearance for its MiniMed Go™ app and Smart Multiple Daily Injection system, which integrates the InPen™ smart insulin pen with Abbott’s Instinct continuous glucose sensor. Approved for users aged 7 and older (and for children 2–6 under caregiver supervision), the system automates dose calculations, issues missed‐dose alerts and delivers actionable guidance. Real-world data from 1,852 users of the prior Smart MDI system showed Time in Range increased from 55.7 percent to 67.2 percent when users responded to more than 75 percent of missed‐dose alerts within an hour, and reached 71.5 percent when high‐glucose alerts were acted upon within the same timeframe. Commercial launch is expected in spring 2026, targeting more than 15 million patients worldwide on multiple daily injections.